Engineered Cancer Nanovaccines:A New Frontier in Cancer Therapy  

作　　者：Yijie Wang Congrui Liu Chao Fang Qiuxia Peng Wen Qin Xuebing Yan Kun Zhang 

机构地区：[1]Central Laboratory and Department of Medical Ultrasound,Sichuan Academy of Medical Sciences,Sichuan Provincial People’s Hospital,School of Medicine,University of Electronic Science and Technology of China,No.32,West Second Section,First Ring Road,Chengdu 610072,People’s Republic of China [2]Department of Stomatology and Central Laboratory,School of Medicine,Shanghai Tenth People’s Hospital,Tongji University,NO.301 Yan‑Chang‑Zhong Road,Shanghai 200072,People’s Republic of China [3]Jiangsu Provincial Innovation and Practice Base for Postdoctors,Suining People’s Hospital,Affiliated Hospital of Xuzhou Medical University,No.2,Bayi West Road,Suining,Xu Zhou 221000,Jiangsu Province,People’s Republic of China

出　　处：《Nano-Micro Letters》2025年第2期134-168,共35页纳微快报（英文版）

基　　金：financially supported by Excellent Young Science Fund for National Natural Science Foundation of China(82022033);Sichuan Science and Technology Program(2024NSFJQ0048);National Natural Science Foundation of China(81902422);Jiangsu Natural Science Foundation(No.BK20231245);Program of Jiangsu Commission of Health(No.M2020024);Program of Yangzhou Commission of Health(No.2023-2-01,2024-2-08).

摘　　要：Vaccinations are essential for preventing and treating disease,especially cancer nanovaccines,which have gained considerable interest recently for their strong anti-tumor immune capabilities.Vaccines can prompt the immune system to generate antibodies and activate various immune cells,leading to a response against tumor tissues and reducing the negative effects and recurrence risks of traditional chemotherapy and surgery.To enhance the flexibility and targeting of vaccines,nanovaccines utilize nanotechnology to encapsulate or carry antigens at the nanoscale level,enabling more controlled and precise drug delivery to enhance immune responses.Cancer nanovaccines function by encapsulating tumor-specific antigens or tumor-associated antigens within nanomaterials.The small size of these nanomaterials allows for precise targeting of T cells,dendritic cells,or cancer cells,thereby eliciting a more potent anti-tumor response.In this paper,we focus on the classification of carriers for cancer nanovaccines,the roles of different target cells,and clinically tested cancer nanovaccines,discussing strategies for effectively inducing cytotoxic T lymphocytes responses and optimizing antigen presentation,while also looking ahead to the translational challenges of moving from animal experiments to clinical trials.

关 键 词：Cancer nanovaccines IMMUNOTHERAPY NANOBIOTECHNOLOGY Immune targets Signaling pathway 

分 类 号：R730.5[医药卫生—肿瘤] TB383.1[医药卫生—临床医学]